119 related articles for article (PubMed ID: 16410134)
1. c-Myc inhibition negatively impacts lymphoma growth.
Gomez-Curet I; Perkins RS; Bennett R; Feidler KL; Dunn SP; Krueger LJ
J Pediatr Surg; 2006 Jan; 41(1):207-11; discussion 207-11. PubMed ID: 16410134
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
4. Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.
De Falco G; Ambrosio MR; Fuligni F; Onnis A; Bellan C; Rocca BJ; Navari M; Etebari M; Mundo L; Gazaneo S; Facchetti F; Pileri SA; Leoncini L; Piccaluga PP
BMC Cancer; 2015 Oct; 15():668. PubMed ID: 26453442
[TBL] [Abstract][Full Text] [Related]
5. Different Mechanisms of Regulation of the Warburg Effect in Lymphoblastoid and Burkitt Lymphoma Cells.
Mushtaq M; Darekar S; Klein G; Kashuba E
PLoS One; 2015; 10(8):e0136142. PubMed ID: 26312753
[TBL] [Abstract][Full Text] [Related]
6. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
7. Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma.
Sáez AI; Artiga MJ; Romero C; Rodríguez S; Cigudosa JC; Pérez-Rosado A; Fernández I; Sánchez-Beato M; Sánchez E; Mollejo M; Piris MA
Lab Invest; 2003 Feb; 83(2):143-52. PubMed ID: 12594230
[TBL] [Abstract][Full Text] [Related]
8. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.
Li Z; Van Calcar S; Qu C; Cavenee WK; Zhang MQ; Ren B
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8164-9. PubMed ID: 12808131
[TBL] [Abstract][Full Text] [Related]
9. Inauhzin(c) inactivates c-Myc independently of p53.
Jung JH; Liao JM; Zhang Q; Zeng S; Nguyen D; Hao Q; Zhou X; Cao B; Kim SH; Lu H
Cancer Biol Ther; 2015; 16(3):412-9. PubMed ID: 25692307
[TBL] [Abstract][Full Text] [Related]
10. The effects of a growth-inhibiting tripeptide, acetylGlu-Ser-GlyNH2 (Ac-ESG), on gene expression and cell cycle progression of two lymphoma cell lines.
Liu Y; Reichelt WH; Luna L; Elgjo K; Reichelt KL
Anticancer Res; 2003; 23(4):3159-65. PubMed ID: 12926049
[TBL] [Abstract][Full Text] [Related]
11. MYC and aggressive B-cell lymphomas.
Slack GW; Gascoyne RD
Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
[TBL] [Abstract][Full Text] [Related]
12. Myc suppression of Nfkb2 accelerates lymphomagenesis.
Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
[TBL] [Abstract][Full Text] [Related]
13. Regulation of c-fgr proto-oncogene expression in Burkitt's lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels.
Sharp NA; Luscombe MJ; Clemens MJ
Oncogene; 1989 Aug; 4(8):1043-6. PubMed ID: 2548145
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel Myc target genes with a potential role in lymphomagenesis.
Marinkovic D; Marinkovic T; Kokai E; Barth T; Möller P; Wirth T
Nucleic Acids Res; 2004; 32(18):5368-78. PubMed ID: 15477387
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia.
Ge Z; Guo X; Li J; Hartman M; Kawasawa YI; Dovat S; Song C
Oncotarget; 2015 Dec; 6(39):42300-11. PubMed ID: 26517351
[TBL] [Abstract][Full Text] [Related]
16. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
Lindström MS; Klangby U; Wiman KG
Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
[TBL] [Abstract][Full Text] [Related]
17. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
Cancer; 2008 Feb; 112(3):552-61. PubMed ID: 18085637
[TBL] [Abstract][Full Text] [Related]
18. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
19. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
